Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAM.
Hountondji L, Faure S, Palassin P, Viel PWD, Dupuy M, Larrey D, Lamoureux A, Coustal C, Pureur D, Lesage C, Assenat É, Rivière B, Faillie JL, Quantin X, Pageaux GP, Maria ATJ, Meunier L. Hountondji L, et al. Among authors: lesage c. Aliment Pharmacol Ther. 2024 Dec;60(11-12):1561-1572. doi: 10.1111/apt.18276. Epub 2024 Sep 24. Aliment Pharmacol Ther. 2024. PMID: 39315730 Free PMC article.
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.
Hountondji L, Ferreira De Matos C, Lebossé F, Quantin X, Lesage C, Palassin P, Rivet V, Faure S, Pageaux GP, Assenat É, Alric L, Zahhaf A, Larrey D, Witkowski Durand Viel P, Riviere B, Janick S, Dalle S, Maria ATJ, Comont T, Meunier L. Hountondji L, et al. Among authors: lesage c. JHEP Rep. 2023 Mar 7;5(6):100719. doi: 10.1016/j.jhepr.2023.100719. eCollection 2023 Jun. JHEP Rep. 2023. PMID: 37138674 Free PMC article.
Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.
Coustal C, Vanoverschelde J, Quantin X, Lesage C, Michot JM, Lappara A, Ederhy S, Assenat E, Faure M, Issa N, Lambotte O, Puyade M, Dereure O, Tosi D, Rullier P, Serre I, Larcher R, Klouche K, Chanques G, Vernhet-Kovacsik H, Faillie JL, Agullo A, Roubille F, Guilpain P, Maria ATJ. Coustal C, et al. Among authors: lesage c. J Immunother Cancer. 2023 May;11(5):e004792. doi: 10.1136/jitc-2022-004792. J Immunother Cancer. 2023. PMID: 37258037 Free PMC article.
Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database.
Nguyễn T, Maria ATJ, Ladhari C, Palassin P, Quantin X, Lesage C, Taïeb G, Ayrignac X, Rullier P, Hillaire-Buys D, Lambotte O, Guilpain P, Faillie JL. Nguyễn T, et al. Among authors: lesage c. Ann Rheum Dis. 2022 Feb;81(2):e32. doi: 10.1136/annrheumdis-2020-217018. Epub 2020 Feb 17. Ann Rheum Dis. 2022. PMID: 32066555 Free article. No abstract available.
[Management of immune-related toxicities associated with immune checkpoints inhibitors: Data from the multidisciplinary meeting « ToxImmun » in Eastern Occitania].
Rivet V, Quantin X, Faillie JL, Lesage C, Meunier L, Faure S, Hillaire-Buys D, Lesouder C, Fabre S, Assenat E, Rullier P, Guilpain P, Maria ATJ. Rivet V, et al. Among authors: lesage c. Rev Med Interne. 2021 May;42(5):310-319. doi: 10.1016/j.revmed.2021.01.002. Epub 2021 Jan 21. Rev Med Interne. 2021. PMID: 33485701 French.
Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Fabre M, Lamoureux A, Meunier L, Samaran Q, Lesage C, Girard C, Du Thanh A, Moulis L, Dereure O. Fabre M, et al. Among authors: lesage c. Melanoma Res. 2024 Jun 1;34(3):241-247. doi: 10.1097/CMR.0000000000000963. Epub 2024 Mar 28. Melanoma Res. 2024. PMID: 38546723
Myasthenia Gravis Induced by Immune Checkpoint Inhibitors.
Becquart O, Lacotte J, Malissart P, Nadal J, Lesage C, Guillot B, Du Thanh A. Becquart O, et al. Among authors: lesage c. J Immunother. 2019 Oct;42(8):309-312. doi: 10.1097/CJI.0000000000000278. J Immunother. 2019. PMID: 31246640 Review.
Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma.
Connell E, Gerard É, Oules B, Brunet-Possenti F, Lamoureux A, Bonnefille H, Mary-Prey S, Carrasquilla A, Mouret S, Kramkimel N, Lesage C, Stoebner PE, Bartoli A, Monestier S, Correard F, Gros A, Jeanson A, Ouafik L, Gaudy-Marqueste C, Tomasini P, Charles J, Amini-Adle M, Malissen N. Connell E, et al. Among authors: lesage c. Oncologist. 2024 Sep 6;29(9):e1180-e1188. doi: 10.1093/oncolo/oyae085. Oncologist. 2024. PMID: 38761384 Free PMC article.
Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.
Lesage C, Longvert C, Prey S, Maanaoui S, Dréno B, Machet L, Zehou O, Kramkimel N, Jeudy G, Skowron F, Aubin F, Visseaux L, Mansard S, Dereure O, Lesage FX, Guillot B; French Group of Onco-Dermatology. Lesage C, et al. Among authors: lesage fx. J Immunother. 2019 Jun;42(5):175-179. doi: 10.1097/CJI.0000000000000268. J Immunother. 2019. PMID: 31090656
74 results